Lasser, Robert

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

for the SCarlet RoAD Investigators, Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., et al. (2017) · Alzheimer's Research & Therapy

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 567

Effect of Zuranolone vs Placebo in Postpartum Depression

Deligiannidis, K. M., Meltzer-Brody, S., Gunduz-Bruce, H., Doherty, J., Jonas, J., Li, S., Sankoh, A. J., Silber, C., Campbell, A. D., Werneburg, B., et al. (2021) · JAMA Psychiatry

Maternal Mental Health During Pregnancy and PostpartumTreatment of Major Depression

Cited by 277

Trial of SAGE-217 in Patients with Major Depressive Disorder

Gunduz-Bruce, H., Silber, C., Kaul, I., Rothschild, A. J., Riesenberg, R., Sankoh, A. J., Li, H., Lasser, R., Zorumski, C. F., Rubinow, D. R., et al. (2019) · New England Journal of Medicine

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 232

Zuranolone for the Treatment of Postpartum Depression

Deligiannidis, K. M., Meltzer-Brody, S., Maximos, B., Peeper, E. Q., Freeman, M., Lasser, R., Bullock, A., Kotecha, M., Li, S., Forrestal, F., et al. (2023) · American Journal of Psychiatry

Maternal Mental Health During Pregnancy and PostpartumTreatment of Major Depression

Cited by 192

Combining Serotonin Reuptake Inhibitors and Bupropion in Partial Responders to Antidepressant Monotherapy

Bodkin, J. A., Lasser, R. A., Wines, J. D., Gardner, D. M., & Baldessarini, R. J. (1997) · The Journal of Clinical Psychiatry

Treatment of Major DepressionBipolar Disorder and Treatment

Cited by 159

Comparison of the burden of illness for adults with ADHD across seven countries: a qualitative study

Brod, M., Pohlman, B., Lasser, R., & Hodgkins, P. (2012) · Health and Quality of Life Outcomes

Attention Deficit Hyperactivity DisorderSubstance Abuse Treatment and Outcomes

Cited by 102

Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo‐Controlled Phase 3 Trial

Clayton, A. H., Lasser, R., Parikh, S. V., Iosifescu, D. V., Jung, J., Kotecha, M., Forrestal, F., Jonas, J., Kanes, S. J., & Doherty, J. (2023) · American Journal of Psychiatry

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 87

Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder

Madhoo, M., Keefe, R. S., Roth, R. M., Sambunaris, A., Wu, J., Trivedi, M. H., Anderson, C. S., & Lasser, R. (2014) · Neuropsychopharmacology

Treatment of Major DepressionAttention Deficit Hyperactivity Disorder

Cited by 74

Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/ Hyperactivity Disorder Who Report Clinically Significant Impairment in Executive Function: Results From a Randomized, Double-Blind, Placebo-Controlled Study

Adler, L. A., Dirks, B., Deas, P. F., Raychaudhuri, A., Dauphin, M. R., Lasser, R. A., & Weisler, R. H. (2013) · The Journal of Clinical Psychiatry

Attention Deficit Hyperactivity DisorderNeurotransmitter Receptor Influence on Behavior

Cited by 62

Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130

Stübner, S., Schön, T., Padberg, F., Teipel, S. J., Schwarz, M. J., Haslinger, A., Buch, K., Dukoff, R., Lasser, R., Müller, N., et al. (1999) · Neuroscience Letters

Tryptophan and brain disordersCytokine Signaling Pathways and Interactions

Cited by 59

A Randomized Controlled Trial of the Efficacy and Safety of Lisdexamfetamine Dimesylate as Augmentation Therapy in Adults With Residual Symptoms of Major Depressive Disorder After Treatment With Escitalopram

Trivedi, M. H., Cutler, A. J., Richards, C., Lasser, R., Geibel, B. B., Gao, J., Sambunaris, A., & Patkar, A. A. (2013) · The Journal of Clinical Psychiatry

Treatment of Major DepressionBipolar Disorder and Treatment

Cited by 58

The Effects of Lisdexamfetamine Dimesylate on Emotional Lability in Children 6 to 12 Years of Age With ADHD in a Double-Blind Placebo-Controlled Trial

Childress, A. C., Arnold, V., Adeyi, B., Dirks, B., Babcock, T., Scheckner, B., Lasser, R., & Lopez, F. A. (2014) · Journal of Attention Disorders

Attention Deficit Hyperactivity DisorderPharmacology and Obesity Treatment

Cited by 33

Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval

Gharabawi, G. M., Gearhart, N. C., Lasser, R. A., Mahmoud, R. A., Zhu, Y., Mannaert, E., Naessens, I., Bossie, C. A., Kujawa, M., & Simpson, G. M. (2007) · Annals of General Psychiatry

Schizophrenia research and treatmentTreatment of Major Depression

Cited by 27

Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity

Ginsberg, L., Katic, A., Adeyi, B., Dirks, B., Babcock, T., Lasser, R., Scheckner, B., & Adler, L. A. (2011) · Current Medical Research and Opinion

Attention Deficit Hyperactivity DisorderPharmacology and Obesity Treatment

Cited by 26

Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis

Jain, R., Babcock, T., Burtea, T., Dirks, B., Adeyi, B., Scheckner, B., & Lasser, R. (2011) · Child and Adolescent Psychiatry and Mental Health

Attention Deficit Hyperactivity DisorderPharmaceutical studies and practices

Cited by 26

Executive Function Deficits in Children with Attention-Deficit/Hyperactivity Disorder and Improvement with Lisdexamfetamine Dimesylate in an Open-Label Study

Turgay, A., Ginsberg, L., Sarkis, E., Jain, R., Adeyi, B., Gao, J., Dirks, B., Babcock, T., Scheckner, B., Richards, C., et al. (2010) · Journal of Child and Adolescent Psychopharmacology

Attention Deficit Hyperactivity DisorderDevelopmental and Educational Neuropsychology

Cited by 23

ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years

López, F. A., Childress, A., Adeyi, B., Dirks, B., Babcock, T., Scheckner, B., Lasser, R. A., Shepski, J., & Arnold, V. (2017) · Journal of Attention Disorders

Attention Deficit Hyperactivity DisorderPharmaceutical studies and practices

Cited by 11

Clinically Relevant Changes in Emotional Expression in Children With ADHD Treated With Lisdexamfetamine Dimesylate

Katic, A., Ginsberg, L., Jain, R., Adeyi, B., Dirks, B., Babcock, T., Scheckner, B., Richards, C., Lasser, R., Turgay, A., et al. (2012) · Journal of Attention Disorders

Attention Deficit Hyperactivity DisorderChild and Adolescent Psychosocial and Emotional Development

Cited by 10

Efficacy and Safety of Lisdexamfetamine Dimesylate in Children with Attention-Deficit/Hyperactivity Disorder and Recent Methylphenidate Use

Jain, R., Babcock, T., Burtea, T., Dirks, B., Adeyi, B., Scheckner, B., Lasser, R., Renna, J., & Duncan, D. (2013) · Advances in Therapy

Attention Deficit Hyperactivity DisorderPharmaceutical studies and practices

Cited by 9

[P1–045]: THE EFFECT OF 6 MONTHS’ DOSING ON THE RATE OF AMYLOID‐RELATED IMAGING ABNORMALITIES (ARIA) IN THE MARGUERITE ROAD STUDY

Abi‐Saab, D., Andjelkovic, M., Delmar, P., Voyle, N., Esau, N., & Lasser, R. A. (2017) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 9